A number of current chemotherapy drugs could prove to be effective treatments for other types of cancer, which then previously believed a comprehensive study in compendia Bioscience.
A drug that can offer advanced usage (as identified by the research team) is Heceptin. Herceptin has long as an effective targeted treatment for people with cancer breast tumors were allowed, have overexpression of human epidermal growth factor receptor 2 (HER2). This genetic mutation makes difficult with traditional medicines to treat the disease.
Recently, the FDA expanded the use of Herceptin as a viable treatment option for patients with gastric and Gostroephogeal cancers that have the same HER2 positivity.
Other known drugs that offer a broader scope of use may include Gefitinib (Iressa) and erlotinib (Tarceva).
These drugs can prove effective due to the fact that you specific gene mutations in the target body. Compendia Bioscience removed by an analysis of the genetic makeup of cancer tumours 4,086 patients identified a number of cancers, which have similar mutations.
For the study, the team saw specifically 22 genes that are currently aligned from existing therapies. Among all clients issued 438 DNA reinforcements that were genetically similar enough to suggest you would benefit from existing treatments. This indicates that five to ten percent of current cancer patients with brain breast, colon, lung, ovarian, pancreatic cancer can be treated effectively by drugs, that are currently on the market.
The effectiveness of Herceptin on stomach serves tumours as a first victory for those in the enhanced use of targeted drugs. The FDA approval for advanced use is on a "Trastuzumab for gastric cancer" trial has been completed and published in August 2010.
In the study stomach cancer patients were found with overexpression of HER2 a reduced mortality rate of 26 percent having given Trastuzumab in combination with conventional chemotherapy (compared to chemotherapy alone).
Results of the study compendia Bioscience reported hosted organization for research and treatment of cancer, NCI and American Association for cancer at a Conference of Berlin by the European.
Sources: ModernMedicine.com, NursingTimes.net
